Structure Therapeutics Inc
For the period ended Dec 31, 2023. Filed Mar 8, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 8, 2024
GPCR$21.73+1.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
CONSOLIDATED STATEMENTS OF CASH FLOWS
(IN THOUSANDS)
| | | | | | | |
|---|---|---|---|---|---|---|
| | | | | | | |
| | | | | | | |
| · · YEAR ENDED DECEMBER 31, | ||||||
| | 2023 | 2022 | ||||
| Cash flows from operating activities | | | | | | |
| Net loss | | $(89,620) | | $(51,321) | ||
| Adjustments to reconcile net loss to net cash used in operating activities: | | | | | | |
| Share-based compensation expense | | 8,191 | | 2,514 | ||
| Depreciation expense | | 295 | | 277 | ||
| Accretion of asset retirement obligation | | | 21 | | | — |
| Non-cash lease expense | | 634 | | 347 | ||
| Accretion of net investment discounts | | (5,975) | | (905) | ||
| Changes in operating assets and liabilities: | | | | |||
| Prepaid expenses and other current assets | | (4,037) | | (305) | ||
| Other non-current assets | | 15 | | (60) | ||
| Accounts payable | | (860) | | 2,153 | ||
| Accrued expenses and other current liabilities | | 12,163 | | 1,541 | ||
| Operating lease liabilities | | (315) | | (361) | ||
| Net cash used in operating activities | | (79,488) | | (46,120) | ||
| Cash flows from investing activities | | | ||||
| Purchases of short-term investments | | (417,356) | | (123,453) | ||
| Maturities of short-term investments | | 151,181 | | 61,500 | ||
| Purchases of property and equipment | | (2,167) | | (155) | ||
| Net cash used in investing activities | | (268,342) | | (62,108) | ||
| Cash flows from financing activities | | | ||||
| Proceeds from issuance of common stock in initial public offering, net of underwriting discount and commissions | | 172,296 | | — | ||
| Proceeds from issuance of Series B redeemable convertible preferred shares, net of issuance costs | | | — | | | 31,500 |
| Proceeds from private placement financing, gross | | | 300,000 | | | — |
| Payments of offering costs | | | (21,565) | | | (2,513) |
| Repurchases of restricted shares | | | — | | | (6) |
| Proceeds from exercise of share options | | 800 | | 33 | ||
| Net cash provided by financing activities | | 451,531 | | 29,014 | ||
| Net change in cash and cash equivalents | | 103,701 | | (79,214) | ||
| Cash and cash equivalents | | | ||||
| Beginning of the period | | 26,091 | | 105,305 | ||
| End of the period | | $129,792 | | $26,091 | ||
| Supplemental disclosures of noncash investing and financing activities | | | ||||
| Conversion of redeemable convertible preferred shares into ordinary shares upon initial public offering | | $199,975 | | $— | ||
| Exchange of ordinary shares to non-voting ordinary shares | | $1 | | $— | ||
| Conversion of non-voting ordinary shares into ordinary shares | | $1 | | $— | ||
| Purchases of property and equipment in accounts payable and accrued expenses and other current liabilities | | $48 | | $— | ||
| Operating lease right-of-use assets obtained in exchange for new lease liabilities | | $5,508 | | $— | ||
| Recognition of asset retirement obligation | | $277 | | $— | ||
| Deferred offering costs included in accounts payable and accrued expenses and other current liabilities | | $53 | | $854 | ||
| Accretion of redeemable convertible preferred shares to their redemption value | | $— | | $1,515 | ||
| | | | | | | |
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.